ECP 2023 Final Programme

Monday, 11 Sept Scientific Programme a Monday 43 ECP 2023 Dublin OFP-05 Oral Free Paper Session 08:30–12:00 Wicklow Meeting Room 1 Pulmonary Pathology Chairs: Izidor Kern, Slovenia M. Angeles Montero Fernandez, United Kingdom Francesca Lunardi, Italy 001 08:30–08:40 A single centre re-evaluation of the correlation of pleural fluid cytology and pleural biopsies in malignant mesothelioma and investigation of inter-observer variability Gayatri Raghuram, United Kingdom A. Loona, I. Soomro 002 08:40–08:50 Reproducibility of c-MET immunohisto- chemistry (clone SP44) interpretation in non-small cell lung carcinoma Christophe Bontoux, France V. Hofman, E. Chamorey, R. Schiappa, S. Lassalle, E. Long-Mira, J. Fayada, C. Bonnetaud, S. Goffinet, M. Ilié, P. Hofman 003 08:50–09:00 Novel ALK Dako-CD246 assay proves to be as competent as the FDA-approved ALK Ventana-D5F3 assay in identifying lung adenocarcinomas with ALK alterations: real-life validation of 188 cases (2011-2023) Ozgur Can Eren, Turkey C. Aydin Mericoz, P. Bulutay, A. Baygul, I. Kulac 004 09:00–09:10 Discrimination of multiple primary lung adenocarcinomas from the intrapulmonary metastasis by using pathologic, radiologic, and molecular correlations Berk Kaan Aktas, Turkey P. Bulutay, B. Aktas, G. Cecikoglu, C. Aydin Mericoz, I. Kulac, K. Ozer, S. Erus, S. Tanju, S. Dilege, C. Atasoy, P. Fırat 005 09:10–09:20 Endobronchial ultrasound guided trans- bronchial needle aspiration (EBUS-TBNA) and EBUS-guided transbronchial mediasti- nal cryobiopsy (EBUS-TMC) in the diagnosis of mediastinal lymphadenopathy: our experience with the technique and proposal on its indication Javier Martin Lopez, Spain G. Diaz Nuevo, E. Tejerina Gonzalez, D. Garcia Fresnadillo, C. Lopez García-Gallo, C. Salas Anton 006 09:20–09:30 Histological, immunohistological and molecular characterisation of congenital pulmonary airway malformation (CPAM) Maximilian Von Laffert, Germany S. Schweitzer, M. Lacher, O. Aubert, F. Hirsch, D. Gräfe, K. Hauptmann, A. Arnold, D. Horst, M. Chirica, F. Klauschen, U. Obeck, M. Boeschen, M. Stiller, H. Bläker 007 10:30–10:40 National testing rate and prevalence of MET exon 14 skipping mutations in NSCLC in the Netherlands Vincent De Jager, The Netherlands B. Cajiao Garcia, A. van der Wekken, L. van Kempen, E. Schuuring, S. Willems 008 10:40–10:50 Predicting the evolution of lung squamous cell carcinoma in situ using deep learning Alon Vigdorovits, Romania G. Olteanu, O. Tica, M. Boros, O. Pop 009 10:50–11:00 The role and importance of BAP1, MTAP and 5-HMC immunohistochemical markers in diagnosis and prognosis in pleural malignant mesothelioma Busra Nur Ates, Turkey E. Kilic Bagir, I. Karacaoglu, D. Gümürdülü 010 11:00–11:10 Small samples, big insights: evaluating PD-L1 expression and interobserver variability in NSCLC Nuray Tezcan, Turkey L. Gucer, C. Aydin Mericoz, P. Bulutay, P. Firat, I. Kulac